✦ LIBER ✦

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo

✍ Scribed by Kenneth R. LaMontagne; Jeannene Butler; Virna B. Borowski; Angel R. Fuentes-Pesquera; Jonathan M. Blevitt; Shenlin Huang; Ronghua Li; Peter J. Connolly; Lee M. Greenberger

Publisher: Springer
Year: 2009
Tongue: English
Weight: 432 KB
Volume: 12
Category: Article
ISSN: 0969-6970
DOI: 10.1007/s10456-009-9151-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo

✍ Nicholas B. Lydon; Helmut Mett; Marcel Mueller; Michael Becker; Robert M. Cozens 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 243 KB 👁 2 views

PTK787/ZK 222584, a small molecule tyros

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

✍ Francis J. Giles; Alan F. List; Michael Carroll; Jorge E. Cortes; Joyce Valickas 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int. J. Cancer,76, 154–163 (1998)

✍ N. Lydon; H. Mett; M. Mueller; M. Becker; R.M. Cozens; D. Daniels; P. Traxler; E 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 8 KB 👁 2 views

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

PTK787/ZK222584, a tyrosine kinase inhib

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

✍ Markus Rudin; Paul M. J. McSheehy; Peter R. Allegrini; Martin Rausch; Diana Baum 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 793 KB

## Abstract Assessment of tumour vascularity may characterize malignancy as well as predict responsiveness to anti‐angiogenic therapy. Non‐invasive measurement of tumour perfusion and blood vessel permeability assessed as the transfer constant, __K__^trans^, can be provided by dynamic contrast‐enha